Yen-Chun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yen-Chun Liu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chi-Ming Chu
College of Public Health National Defense Medical University Taipei City Taiwan
1 shared publication - Chi-Tun Tang
Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan
1 shared publication - Chia-Yang Shiau
Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan
1 shared publication - Gwo-Jang Wu
Graduate Institute of Medical Sciences and Department of Obstetrics & Gynecology, Tri-Service General Hospital, National Defense Medical Center , Taipei 11490
1 shared publication - Meng-Chang Lee
School of Public Health, National Defense Medical Center, Taipei, Taiwan, ROC
1 shared publication - Wei-Zhi Lin
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan
1 shared publication
Latest Publications
- Open Access
- 4 February 2022
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 20 (1) , 1-13
From GWAS to drug screening: repurposing antipsychotics for glioblastoma
Background: Glioblastoma is currently an incurable cancer. Genome-wide association studies have demonstrated that 41 genetic variants are associated with glioblastoma and may provide an option for drug development. Methods: We investigated FDA-approved antipsychotics for their potential treatment of glioblastoma based on genome-wide association studies data using a ‘pathway/gene-set analysis’ approach. Results: The in-silico screening led to the discovery of 12 candidate drugs. DepMap portal revealed that 42 glioma cell lines show higher sensitivities to 12 candidate drugs than to Temozolomide, the current standard treatment for glioblastoma. Conclusion: In particular, cell lines showed significantly higher sensitivities to Norcyclobenzaprine and Protriptyline which were predicted to bind targets to disrupt a certain molecular function such as DNA repair, response to hormones, or DNA-templated transcription, and may lead to an effect on survival-related pathways including cell cycle arrest, response to ER stress, glucose transport, and regulation of autophagy. However, it is recommended that their mechanism of action and efficacy are further determined.
- 4 February 2022
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 20 (1) , 1-13
Open AccessFrom GWAS to drug screening: repurposing antipsychotics for glioblastoma
Background: Glioblastoma is currently an incurable cancer. Genome-wide association studies have demonstrated that 41 genetic variants are associated with glioblastoma and may provide an option for drug development. Methods: We investigated FDA-approved antipsychotics for their potential treatment of glioblastoma based on genome-wide association studies data using a ‘pathway/gene-set analysis’ approach. Results: The in-silico screening led to the discovery of 12 candidate drugs. DepMap portal revealed that 42 glioma cell lines show higher sensitivities to 12 candidate drugs than to Temozolomide, the current standard treatment for glioblastoma. Conclusion: In particular, cell lines showed significantly higher sensitivities to Norcyclobenzaprine and Protriptyline which were predicted to bind targets to disrupt a certain molecular function such as DNA repair, response to hormones, or DNA-templated transcription, and may lead to an effect on survival-related pathways including cell cycle arrest, response to ER stress, glucose transport, and regulation of autophagy. However, it is recommended that their mechanism of action and efficacy are further determined.